Table 2.
Estimated relative rate of factors independently associated with initiation of lipid-lowering therapy.
| Model including lipid parameters |
Model excluding lipid parameters |
|||
|---|---|---|---|---|
| Variable | Relative rate (95% CI) | P | Relative rate (95% CI) | P |
| Male sex | 1.19 (1.04–1.37) | .01 | 1.43 (1.27–1.61) | <.001 |
| Age (per 5 years older) | 1.14 (1.12–1.17) | <.001 | 1.18 (1.15–1.20) | <.001 |
| BMI | ||||
| <18.0 | 0.72 (0.53–0.97) | .01 | 0.70 (0.53–0.92) | <.001 |
| ⩾18.0–26.0 | 1 | 1 | ||
| ⩾26.1–30.0 | 1.04 (0.92–1.18) | 1.29 (1.16–1.44) | ||
| ⩾30.1 | 1.28 (1.05–1.57) | 1.38 (1.14–1.66) | ||
| Not known | 0.93 (0.83–1.05) | 1.00 (0.90–1.10) | ||
| Risk group | ||||
| Men who have sex with men | 1 | <.001 | 1 | <.001 |
| Injection drug user | 0.64 (0.55–0.75) | 0.46 (0.40–0.53) | ||
| Heterosexual | 0.94 (0.85–1.06) | 0.94 (0.85–1.04) | ||
| Other/unknown | 1.02 (0.86–1.20) | 0.91 (0.79–1.06) | ||
| Family history of CVD | 1.20 (1.05–1.38) | .01 | 1.34 (1.18–1.51) | <.001 |
| Diagnosis of diabetes mellitus | 1.47 (1.28–1.70) | <.001 | 1.81 (1.59–2.07) | <.001 |
| Previous cardiovascular event | 3.47 (2.96–4.07) | <.001 | 3.64 (3.15–4.21) | <.001 |
| Cumulative exposure to cART (per year) | 1.08 (1.06–1.10) | <.001 | 1.16 (1.14–1.18) | <.001 |
| Calendar period | ||||
| 1999–2000 | 1 | <.001 | 1 | <.001 |
| 2001 | 1.03 (0.88–1.21) | 0.98 (0.86–1.12) | ||
| 2002 | 0.98 (0.83–1.16) | 0.76 (0.66–0.87) | ||
| 2003 | 0.91 (0.77–1.08) | 0.68 (0.59–0.78) | ||
| 2004 | 0.80 (0.67–0.95) | 0.52 (0.45–0.61) | ||
| 2005–2006 | 0.59 (0.49–0.71) | 0.36 (0.31–0.43) | ||
| Latest TC level (per mmol/L higher)a | 1.52 (1.49–1.55) | <.001 | NA | |
| Latest HDLC level (per mmol/L lower)a | 0.67 (0.59–0.74) | <.001 | NA | |
| Latest TG level (per mmol/L higher)a | 1.10 (1.08–1.11) | <.001 | NA | |
NOTE. Analyses include data for 28,985 patients from 10 of the 11 cohorts. BMI, body mass index (calculated as the weight in kilograms divided by the square of the height in meters); cART, combination antiretroviral therapy; CVD, cardiovascular disease; HDLC, high-density lipoprotein cholesterol; NA, not applicable; TC, total cholesterol; TG, triglyceride.
a
Patients without baseline lipid measurements were excluded from the risk set for these analyses until the date of their first available lipid measurement.